Biogen IDEC
Biogen to build billion-dollar plant in Switzerland
July 7, 2015Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis
Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …
Big pharma partners with government over $100m dementia fund
March 17, 2015Research and Development, Sales and Marketing Alzheimer's, Biogen IDEC, GSK, J&J, JJ, Pfizer, government, jp morgan, lilly
Lilly, Pfizer, GSK, J&J and Biogen Idec are set to join a $100m Dementia Discovery Fund to boost research into …
Pharma is boosting pipelines to avoid patent cliff
February 11, 2015Sales and Marketing Biogen IDEC, Moody's, dimethyl fumarate, lilly, pharma, pipelines, sofosbuvir, sovaldi, tecfidera
Pharmaceutical companies have improved their pipelines of new drugs over the last 18 months according to financial analysts Moody’s Investors …
Biogen Idec buys Convergence
January 14, 2015Sales and Marketing BG00010, Biogen IDEC, CNV1014802, Colombia University Medical Center, Convergence, Neublastin
Biogen Idec is to acquire independent UK-based Convergence Pharmaceuticals to strengthen its pipeline of drugs for pain management in a …
Mixed results for Biogen’s MS drug
January 9, 2015Sales and Marketing Anti-LINGO-1, BIIB033, Biogen IDEC, MS, multiple sclerosis, plegridy
An experimental drug from Biogen Idec for the treatment of multiple sclerosis (MS) has shown a mixed bag of results …
Bayer files haemophilia drug in EU
December 5, 2014Sales and Marketing BAY 81-8973, Bayer, Biogen IDEC, EMA, elocta, haemophilia a, kogenate
Bayer has submitted a marketing authorisation application to the EMA for its haemophilia A therapy BAY 81-8973. The German firm’s …
Astellas teams up with Proteostasis against protein defects
November 4, 2014Research and Development, Sales and Marketing Astellas, Biogen IDEC, Protein, Proteostasis, upr
Astellas has announced it will collaborate with Proteostasis Therapeutics to develop drugs for diseases caused by protein defects, using the …
Two neuroscientists join Biogen Idec
October 30, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, richard ransohoff
Christopher Henderson and Richard Ransohoff have joined Biogen Idec to lead the company’s neurology research and discovery efforts. Henderson joins …
Biogen Idec hires senior vice president
October 2, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, gene, olivier danos
US-based biotech firm Biogen Idec has hired Dr Olivier Danos to be the senior vice president of its gene therapy …
Biogen Idec hires from Novartis to head ALS
September 1, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, Novartis, als, donald johns
Biogen Idec has appointed Dr Donald Johns as the vice president of its amyotrophic lateral sclerosis (ALS) innovation hub unit. …
Alzheimer’s tie-up for Eisai and Biogen
March 6, 2014Research and Development, Sales and Marketing Alzheimer's, BAN2401, Biogen IDEC, E2609, Eisai
Eisai and Biogen Idec have joined forces to look for new Alzheimer’s treatments, developing and commercialising two of the Japanese …
Biogen Idec’s MS drug gets European approval
February 4, 2014Manufacturing and Production, Sales and Marketing Aubagio, Biogen IDEC, EU, MS, gilenya, tecdifera
Biogen Idec’s oral multiple sclerosis drug Tecfidera has won approval in Europe as a first-line treatment for people with relapsing-remitting …
Strong sales for Biogen Idec’s MS drug
October 29, 2013Sales and Marketing Biogen IDEC, Q3, gilenya, tecfidera
Biogen Idec’s oral multiple sclerosis (MS) drug Tecfidera lived up to its blockbuster-in-waiting billing with third quarter sales that exceeded …
Circassia appoints new chairman from Biogen Idec
September 26, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biogen IDEC, Circassia, granata
Speciality biopharma firm Circassia has appointed Dr Francesco Granata as its non-executive chairman. Granata is executive in Residence at Warburg …
Amicus links with Biogen Idec
September 12, 2013Research and Development, Sales and Marketing Amicus, Biogen IDEC, Parkinson's
Amicus Therapeutics and Biogen Idec have signed a collaboration agreement which will see them look for novel small molecules for …
Latest content
FibroFind appoints Lee Borthwick as CEO
